

CITATION REPORT

List of articles citing

Clinical development success rates and social value of pediatric Phase 1 trials in oncology

DOI: 10.1371/journal.pone.0234911
PLoS ONE, 2020, 15, e0234911.

Source: <https://exaly.com/paper-pdf/77149035/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
5	Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis. <i>Targeted Oncology</i> , 2021 , 16, 415-424	5	2
4	Improving Early Futility Determination by Learning from External Data in Pediatric Cancer Clinical Trials. <i>Statistics in Biosciences</i> , 1	1.5	
3	Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis. <i>BMC Medicine</i> , 2022 , 20,	11.4	0
2	A decade of FDA approvals for pediatric cancer indications: What have we learned?. 2023 , 1, 100005		0
1	Characteristics of Scientific Success in Phase 1 Pediatric Oncology Clinical Trials: Establishing a Need for Integrated Patient-Reported Outcomes Even in Early Phase Trials. 2023 , 3, e039		0